Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > A 3rd CR at 450 days?

<< Previous

Bullboard Posts

Next >>

Comment by fredgoodwinsonon Jul 24, 2021 11:30am

173 Views

Post# 33600805

RE:RE:RE:RE:RE:A 3rd CR at 450 days?

Yes GFF still disturbing - and entirely unexplained - as to why they didn`t simply replicate the highly successful and well understood procedure for Patients 5 and 6 in Phase IB at the start of Phase II.

Evidently not alone in being unable to make any sense of the actual position from the garbled presentation of data in past Quarterlies but this time there may be just enough available to point to where we might be going if presented clearly and unambiguously.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023